We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$624M
Turnover
44.83%
1-Year Est. Return
250.2%
This Fund
S&P 500
This Quarter
Est. Return
+7.15%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$3.62B
AUM Growth
+$540M
(+18%)
Cap. Flow
+$630M
Cap. Flow
% of AUM
17.4%
Top 10 Holdings %
Top 10 Hldgs %
34.44%
Holding
132
New
36
Increased
34
Reduced
15
Closed
38
Avg Time Held Equity + Options
0.3
years
Top 10 Avg Time Held Equity + Options
0.3
years
Top 20 Avg Time Held Equity + Options
0.2
years
Avg Time Held Equity only
0.3
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intuitive Surgical
ISRG
|
+$105M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$93.1M |
| 3 |
Medtronic
MDT
|
+$84.8M |
| 4 |
Nuvation Bio
NUVB
|
+$84.1M |
| 5 |
AbbVie
ABBV
|
+$77.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$137M |
| 2 |
Quest Diagnostics
DGX
|
+$94.4M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$87.1M |
| 4 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$57.5M |
| 5 |
Organogenesis Holdings
ORGO
|
+$55M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.12% |
| 2 | Miscellaneous | 1.45% |
| 3 | Financials | 0.43% |
| 4 | Industrials | 0% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
AbbVie
ABBV
$501B
| $225M | 6.21% |
2,077,200
+721,200
| +53% | +$77.1M |
2019 Q4
5 quarters
|
|
2
AstraZeneca
AZN
$259B
| $182M | 5.01% |
1,825,250
+675,250
| +59% | +$67.9M |
2020 Q4
1 quarter
|
|
3
Avantor
AVTR
$10.9B
| $144M | 3.98% |
4,985,100
-1,581,600
| -24% | -$45.7M |
2020 Q2
3 quarters
|
|
|
4
Medtronic
MDT
$122B
| $121M | 3.34% |
1,024,200
+723,200
| +240% | +$84.8M |
2020 Q2
3 quarters
|
|
5
Arvinas
ARVN
$468M
| $116M | 3.21% |
1,760,300
-27,058
| -2% | -$2.07M |
2020 Q2
3 quarters
|
|
|
6
Intuitive Surgical
ISRG
$151B
| $103M | 2.85% |
+418,200
| New | +$105M |
2021 Q1
0 quarters
|
|
7
Maravai LifeSciences
MRVI
$1.05B
| $98.4M | 2.72% |
2,761,545
-684,227
| -20% | -$22.7M |
2020 Q4
1 quarter
|
|
8
Cardinal Health
CAH
$58.7B
| $88.9M | 2.46% |
1,463,000
+655,000
| +81% | +$36.2M |
2020 Q4
1 quarter
|
|
9
Syndax Pharmaceuticals
SNDX
$1.22B
| $86M | 2.38% |
3,846,000
+538,000
| +16% | +$12.2M |
2020 Q2
3 quarters
|
|
10
DELISTED
ESSA Pharma
EPIX
| $82.5M | 2.28% |
2,840,000
+282,000
| +11% | +$6.56M |
2020 Q3
2 quarters
|
|
|
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $81.5M | 2.25% |
475,700
+95,700
| +25% | +$18.9M |
2020 Q3
2 quarters
|
|
|
SGEN
12
DELISTED
Seagen Inc. Common Stock
SGEN
| $80.2M | 2.22% |
+577,900
| New | +$93.1M |
2021 Q1
0 quarters
|
|
13
DELISTED
Exact Sciences
EXAS
| $78.8M | 2.18% |
598,000
+351,000
| +142% | +$48M |
2020 Q4
1 quarter
|
|
|
14
Nuvation Bio
NUVB
$1.67B
| $78.6M | 2.17% |
+7,521,941
| New | +$84.1M |
2021 Q1
0 quarters
|
|
15
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $71.8M | 1.98% |
1,049,800
+558,000
| +113% | +$45.1M |
2020 Q1
4 quarters
|
|
16
Vertex Pharmaceuticals
VRTX
$129B
| $66.8M | 1.85% |
310,900
+163,600
| +111% | +$35.9M |
2020 Q4
1 quarter
|
|
17
NovaBridge Biosciences American Depositary Shares
NBP
$149M
| $64.4M | 1.78% |
1,329,000
-262,000
| -16% | -$14.2M |
2020 Q3
2 quarters
|
|
|
ARNA
18
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $62.4M | 1.72% |
898,550
+277,550
| +45% | +$21.4M |
2020 Q4
1 quarter
|
|
19
Alnylam Pharmaceuticals
ALNY
$31.3B
| $60.4M | 1.67% |
+427,969
| New | +$64.4M |
2021 Q1
0 quarters
|
|
20
Bausch Health
BHC
$2.36B
| $60M | 1.66% |
1,891,300
-80,700
| -4% | -$2.37M |
2020 Q4
1 quarter
|
|
21
DELISTED
CATALENT, INC.
CTLT
| $59M | 1.63% |
560,000
+223,000
| +66% | +$24.9M |
2020 Q3
2 quarters
|
|
22
Zentalis Pharmaceuticals
ZNTL
$212M
| $54.8M | 1.51% |
1,263,300
+128,300
| +11% | +$5.52M |
2020 Q2
3 quarters
|
|
|
HZNP
23
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $53.5M | 1.48% |
581,000
-588,300
| -50% | -$49.6M |
2019 Q4
5 quarters
|
|
24
DELISTED
Blueprint Medicines
BPMC
| $53.1M | 1.47% |
546,000
+306,000
| +128% | +$30.6M |
2020 Q4
1 quarter
|
|
25
Zimmer Biomet
ZBH
$18B
| $52.2M | 1.44% |
+335,780
| New | +$52M |
2021 Q1
0 quarters
|
|
Similar funds
ANB
RIP
TAM
B
PWS
LWP
FGA
BVC
Avidity Partners Management's Q1 2021 Portfolio in Review
As of Q1 2021, Avidity Partners Management held 132 positions worth $3.62B, up 18% from $3.08B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Avidity Partners Management deployed $630M of net new capital in Q1 2021, opening 36 new positions and adding to 34 existing holdings. Its largest new stake was Intuitive Surgical: 418,200 shares worth $103M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Organogenesis Holdings, an estimated $55M trimmed.
- Avidity Partners Management's largest Q1 2021 buy was Intuitive Surgical: 418,200 shares worth $103M.
- Avidity Partners Management added most to Medtronic in Q1 2021, an estimated $84.8M increase.
- Avidity Partners Management's biggest Q1 2021 reduction was Organogenesis Holdings, cutting an estimated $55M.
- Avidity Partners Management fully exited Eli Lilly in Q1 2021, selling an estimated $137M.
- Avidity Partners Management's ten largest holdings make up 34% of its $3.62B portfolio in Q1 2021.
- Avidity Partners Management opened 36 new positions and closed 38 in Q1 2021.
- Avidity Partners Management's portfolio value rose 18% quarter-over-quarter to $3.62B.
Based on Avidity Partners Management's 13F filing for Q1 2021, filed 17 May 2021.